James Montier: valuations are way too high

The market is completely discounting the risk to the economy and operating as if there is nothing to worry about, pricing in a V-shaped recovery, says James Montier, investment strategist at GMO.

James Montier, investment strategist, GMO

Investors normally overreact at extremes, James Montier, the value-investing guru who serves on GMO’s asset allocation team, tells Barron’s: they value stocks at “peak multiples on peak earnings and trough multiples on trough earnings”. But this time, it’s different. “Instead of following the collapse in earnings, the market is completely discounting [the risk] and operating as if there is nothing to worry about … and has priced in a V-shaped recovery.” 

Yet even if earnings were to rebound, valuations still seem expensive. The economic expansion that ended with the Covid-19 crisis “was the longest but also the weakest economic recovery on record” and stockmarket gains have run ahead of earnings growth. That’s especially true in America, where rising valuations and share buybacks have been responsible for virtually all the superior performance of US stocks over the rest of the world, as Montier noted in a research report before the pandemic arrived in March.

So most assets are making no allowance for the potential risks. Small caps look especially vulnerable to a severe recession, but even larger stocks that have done well so far – ie, big tech – “are probably only relative winners … Google and Facebook … aren’t going to see an increase in advertising revenue, so it’s not clear they win in an absolute sense”. Only emerging markets look cheap enough. “Everybody and their mother hates emerging markets,” which gives you a “much greater margin of safety.”

Recommended

The MoneyWeek Podcast: Stephen Yiu on why, in a low quality market, you should buy only the best stocks – and don't over diversify
Investment strategy

The MoneyWeek Podcast: Stephen Yiu on why, in a low quality market, you should buy only the best stocks – and don't over diversify

Merryn talks to Stephen Yiu of the Blue Whale Growth Fund about his investment approach and the sectors he likes, plus why you should stick with top q…
2 Dec 2020
Too embarrassed to ask: what are “bulls” and “bears”?
Too embarrassed to ask

Too embarrassed to ask: what are “bulls” and “bears”?

Two common terms you’ll hear when reading about markets are “bulls” and “bears”. But what do they mean? 
1 Dec 2020
Great frauds in history: Meyer Blinder's Blind ’em & Rob ’em
People

Great frauds in history: Meyer Blinder's Blind ’em & Rob ’em

Meyer Blinder’s brokerage firm cold-called unsuspecting punters and pumped shares in fraudulent shell companies while stiffing them with huge commiss…
1 Dec 2020
Vaccines, value investing and UK stocks
Value investing

Vaccines, value investing and UK stocks

Vaccines promise a return to normal life. And that bodes well for “value” stocks, says Merryn Somerset Webb – and for the UK market in particular.
30 Nov 2020

Most Popular

This week’s rally in value stocks is just the beginning
Value investing

This week’s rally in value stocks is just the beginning

The arrival of a vaccine this week saw huge gains in the markets and investors switching out of big-tech growth stocks and into “value” stocks in more…
13 Nov 2020
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Nov 2020
Time for investors to be fearful, not greedy – and sell?
Investment strategy

Time for investors to be fearful, not greedy – and sell?

The Covid-19 crash proved a great investment opportunity. Does the vaccine mean it’s time to sell?
23 Nov 2020